Silverarc Capital Management’s Immunovant IMVT Stock Holding History

Silverarc Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.9M	Buy	619,096 +204,860	+49%	+$6.24M	2.48%	12
2026 Q1	$10.3M	Buy	+414,236	New	+$10.7M	1.05%	26
2025 Q4	–	Sell	-50,000	Closed	-$806K	–	84
2025 Q3	$806K	Buy	+50,000	New	+$809K	0.11%	70
2024 Q1	–	Sell	-20,000	Closed	-$843K	–	85
2023 Q4	$843K	Buy	+20,000	New	+$736K	0.25%	60
2023 Q1	–	Sell	-519,614	Closed	-$9.22M	–	92
2022 Q4	$9.22M	Buy	519,614 +219,614	+73%	+$2.77M	2.64%	9
2022 Q3	$1.67M	Buy	+300,000	New	+$1.47M	0.57%	49
2021 Q2	–	Sell	-50,400	Closed	-$808K	–	107
2021 Q1	$808K	Sell	50,400 -49,600	-50%	-$1.31M	0.44%	58
2020 Q4	$4.62M	Buy	+100,000	New	+$4.62M	2.68%	10

Other funds holding IMVT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Silverarc Capital Management's IMVT Position: Q2 2026 in Review

Silverarc Capital Management increased its Immunovant (IMVT) stake by 49% in Q2 2026, buying an estimated $6.24M and bringing the position to 619,096 shares worth $23.9M. The position accounts for 2.48% of the portfolio, ranked #12.

Silverarc Capital Management first reported a position in IMVT in Q4 2020 and has held it in 8 quarters since. 226 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

Silverarc Capital Management held 619,096 shares of Immunovant worth $23.9M as of Q2 2026.
Silverarc Capital Management bought 204,860 Immunovant shares in Q2 2026, an estimated $6.24M.
Immunovant made up 2.48% of Silverarc Capital Management's portfolio in Q2 2026, its #12 holding.
Silverarc Capital Management first reported a position in Immunovant in Q4 2020 and has held it in 8 quarters since.
226 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.